Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 98.99% | 252.20% | 12.23% | 27.50% | 60.77% |
| Total Depreciation and Amortization | -52.80% | -51.91% | -33.59% | -36.31% | 32.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -200.00% | -- |
| Total Other Non-Cash Items | -25.26% | -57.34% | 45.80% | -160.45% | -83.35% |
| Change in Net Operating Assets | -168.55% | -1,695.17% | 155.80% | -140.76% | -49.25% |
| Cash from Operations | 76.95% | 29.26% | 60.63% | -129.47% | 50.37% |
| Capital Expenditure | -- | -- | -- | -213.95% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 216.67% | -- | -213.95% | 100.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -230.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -49.64% | 44.17% | -- | -- |
| Cash from Financing | 280.32% | 2,278.42% | -94.08% | 122.82% | -102.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.33% | 79.32% | 34.91% | 91.78% | -132.94% |